Godsey & Gibb Associates decreased its position in Pfizer Inc. (NYSE:PFE) by 3.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 391,088 shares of the biopharmaceutical company’s stock after selling 12,156 shares during the quarter. Pfizer accounts for approximately 2.4% of Godsey & Gibb Associates’ holdings, making the stock its 18th largest position. Godsey & Gibb Associates’ holdings in Pfizer were worth $14,165,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently modified their holdings of PFE. Mckinley Capital Management LLC Delaware bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $103,000. Herndon Capital Management LLC bought a new stake in shares of Pfizer in the 2nd quarter worth approximately $120,000. Americafirst Capital Management LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $127,000. Private Vista LLC lifted its holdings in shares of Pfizer by 2,277.3% in the 2nd quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after purchasing an additional 190,933 shares during the last quarter. Finally, Lipe & Dalton lifted its holdings in shares of Pfizer by 6.9% in the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock worth $155,000 after purchasing an additional 300 shares during the last quarter. Institutional investors own 71.16% of the company’s stock.
In other news, insider Mikael Dolsten sold 69,699 shares of the business’s stock in a transaction on Friday, March 9th. The stock was sold at an average price of $36.59, for a total value of $2,550,286.41. Following the sale, the insider now owns 120,784 shares of the company’s stock, valued at approximately $4,419,486.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Rady A. Johnson sold 27,323 shares of the business’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $36.55, for a total value of $998,655.65. Following the completion of the sale, the executive vice president now directly owns 70,332 shares in the company, valued at approximately $2,570,634.60. The disclosure for this sale can be found here. Insiders sold a total of 248,037 shares of company stock worth $9,064,785 in the last three months. Company insiders own 0.06% of the company’s stock.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion for the quarter, compared to the consensus estimate of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.47 EPS. equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.
Pfizer announced that its board has approved a share buyback program on Monday, December 18th that permits the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its shares are undervalued.
Several analysts recently issued reports on the company. BMO Capital Markets set a $43.00 price target on Pfizer and gave the stock a “buy” rating in a report on Tuesday, March 6th. Berenberg Bank set a $36.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. UBS set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Leerink Swann raised their price target on Pfizer from $35.00 to $38.00 and gave the stock a “market perform” rating in a report on Wednesday, January 31st. Finally, Societe Generale set a $40.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Wednesday, January 31st. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $39.40.
TRADEMARK VIOLATION NOTICE: “Godsey & Gibb Associates Decreases Stake in Pfizer Inc. (PFE)” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3298765/godsey-gibb-associates-decreases-stake-in-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.